FDA expands pediatric use of Bristol's HIV drug Sustiva

05/6/2013 | Drug Store News · RTT News

The FDA approved Bristol-Myers Squibb's Sustiva, or efavirenz, to treat HIV-1 patients ages 3 months to 3 years who weigh at least 7.7 pounds. The approval covers sprinkle administration when swallowing a capsule or tablet isn't possible. The drug was evaluated in three open-label trials involving 182 patients.

View Full Article in:

Drug Store News · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA